Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-cash Items (2022 - 2025)

Historic Non-cash Items for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $41.4 million.

  • Phathom Pharmaceuticals' Non-cash Items rose 128982.57% to $41.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year increase of 128982.57%. This contributed to the annual value of $2.9 million for FY2024, which is 8101.38% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Non-cash Items stood at $41.4 million for Q3 2025, which was up 128982.57% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Non-cash Items registered a high of $52.3 million during Q1 2022, and its lowest value of $2.0 million during Q2 2022.
  • For the 4-year period, Phathom Pharmaceuticals' Non-cash Items averaged around $15.8 million, with its median value being $4.4 million (2025).
  • Per our database at Business Quant, Phathom Pharmaceuticals' Non-cash Items plummeted by 9510.58% in 2023 and then skyrocketed by 128982.57% in 2025.
  • Phathom Pharmaceuticals' Non-cash Items (Quarter) stood at $4.5 million in 2022, then soared by 241.82% to $15.3 million in 2023, then crashed by 81.01% to $2.9 million in 2024, then skyrocketed by 1323.6% to $41.4 million in 2025.
  • Its Non-cash Items stands at $41.4 million for Q3 2025, versus $4.4 million for Q2 2025 and $3.6 million for Q1 2025.